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SHORT REPORT
Six novel NPC1 mutations in Chinese patients with
Niemann–Pick disease type C
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In patients with Niemann–Pick disease type C (NPC), an
autosomal recessive lipid storage disorder, neurodegenera-
tion can occur in early life. Vertical ophthalmoplegia and
extrapyramidal signs may be seen. Cholestatic jaundice and
hepatosplenomegaly occur frequently in patients with early
onset disease, with bone marrow biopsies showing diffuse
infiltration of foamy histiocytes. Cholesterol esterification in
skin fibroblasts is reduced, resulting in intracellular accumu-
lation of cholesterol. NPC1 mutations are responsible for the
disease in ,95% of patients. NPC1 encodes a 1278 amino
acid protein which contains 13 transmembrane domains.
Over 130 mutations have been identified in NPC1, with over
a third present within an NPC1 specific cysteine-rich domain
positioned in a large extracellular loop. It has been proposed
that the defect in cholesterol homoeostasis is the cause of
neuronal apoptosis, but the precise role of the NPC1 protein
and the functional implications of its mutations remain
unknown. Although NPC is routinely diagnosed by biochem-
ical analysis, identification of molecular defects helps confirm
the diagnosis and enables family studies, and rapid, accurate
prenatal diagnosis. This report describe the analysis of the
NPC1 gene in five Taiwanese/Chinese patients with NPC.
Six novel NPC1 mutations (N968S, G1015V, G1034R,
V1212L, S738Stop, and I635fs) were identified of which
three are missense mutations located in the cysteine-rich
domain. These are the first NPC1 mutations reported from
Chinese patients with NPC.
N
iemann–Pick disease type C (NPC) is a rare autosomal
recessive neurodegenerative disorder characterised by
intracellular accumulation of unesterified cholesterol
and gangliosides within the endosomal–lysosomal system.1
The incidence is estimated to be about 1 in 100 000 live
births.2 3 NPC is clinically heterogeneous and there is a
broad spectrum of phenotypes with respect to the age of
onset, organomegaly, and neurological disease. In most
cases, neurological symptoms appear between the ages of
4 and 10 years,4 although the timing of onset can range
from perinatal to adulthood. The neurological abnorma-
lities develop insidiously and are manifested as ataxia,
mental deterioration, psychomotor retardation, and
seizures. Pyramidal tract signs, cerebellar ataxia, and extra-
pyramidal features such as dystonia are common.
Supranuclear ophthalmoplegia with paralysis of down gaze
is characteristic in patients with NPC. Cataplexy and various
types of seizure may also occur during the evolution of the
disease.5
Cultured fibroblasts from patients with NPC show a
significant reduction in the rate of cholesterol esterification.6
Filipin staining of these cells reveals the abnormal accumula-
tion of intracellular cholesterol, as evidenced by intense
perinuclear punctate staining. In addition, cerebral neurones
show the presence of neurofibrillary tangles, which are
immunologically and ultrastructurally similar to those found
in the brains of patients affected by Alzheimer’s disease.7
Some patients have cholestatic jaundice, and the infiltration
of foamy histiocytes (Niemann–Pick cells) can be identified
in the bone marrow.
NPC is genetically heterogeneous with two complementa-
tion groups.8 Mutations of the NPC1 gene have been
identified in ,95% of the patients with NPC.9 10 The NPC1
gene, located on chromosome 18q11–12, spans more than
47 kb and contains 25 exons.11 It encodes a 1278 amino acid
protein with 13 transmembrane domains, three large luminal
hydrophilic loops, six cytoplasmic loops, and a cytoplasmic
tail with a dileucine motif.12 13 The third luminal loop
contains an NPC1 specific cysteine-rich domain (residues
855–1098). The NPC1 protein also contains a sterol sensing
domain (residues 616–797), which is homologous to those
found in 3-hydroxy-3-methylglutaryl-coenzyme A reductase
(HMG-R) and sterol regulatory element binding protein
cleavage activating protein.14 Disease causing mutations are
spread throughout the NPC1 gene, although there is a
concentration of mutations within the cysteine-rich domain,
with an apparent hot spot for mutations between residues
927 and 958.15 In addition, the region between amino acids
1038 and 1253, which shares 35% identity with a portion of
the Patched 1 (PTC1) protein, also contains a significant
proportion of mutations.16 Most molecular defects of NPC1
involve only a few nucleotides such as small deletions, small
insertions, or missense mutations (see the human mutation
database17). The functional implications of the mutations to
NPC1 are not yet clear; however, sterol homoeostasis
dysfunction, especially the blockage of cholesterol transport
between the lysosome and sterol regulatory machinery
leading to the excessive accumulation of cholesterol, has
been proposed to be the major cause of neuronal apoptosis in
NPC.18
Based on an analysis of 134 cases, Vanier et al showed that
diagnosis of NPC is best reached by the combined demon-
stration of a deficient induction of esterification and
intravesicular cholesterol storage by filipin staining.19
However, identification of the molecular defect is important
for confirming the diagnosis of NPC as well as enabling rapid
and accurate prenatal diagnosis. Here, we describe the
analysis of the NPC1 gene in five Taiwanese/Chinese patients




Five index patients and their family were studied. All families
were of Taiwanese/Chinese origin. Ethical approval for
Abbreviations: DHPLC, denaturing high performance liquid
chromatography; NPC, Niemann–Pick disease type C
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genetic studies in Niemann–Pick disease type C (NPC) was
obtained from the National Taiwan University Hospital
Ethics Committee.
All index cases were diagnosed as having NPC based on
clinical features, pathology in bone marrow, and biochemical
analysis of cultured fibroblasts using filipin staining and
cholesterol esterification. None of the families had a history
of consanguinity. In all cases the disease started early in life,
usually in the first decade (table 1). Hepatosplenomegaly was
noted in all patients. The neurological features were highly
variable among the families. However, patients within the
same family had a similar neurological presentation (see
table 1, patients 1, 4, and 5). The neurological manifestations
included cerebellar ataxia, cerebral atrophy with psychomo-
tor retardation, speech and mental function deterioration,
and pyramidal as well as extrapyramidal signs (see table 1).
Neuroimaging studies demonstrated dysgenesis of the corpus
callosum with cerebellar or cerebral atrophy in patients 2 and
4. Non-specific high signals in T2-weighted images were seen
in the white matter of brain and spinal cord of patients 1 and
5, respectively (fig 1C). Bone marrow biopsies of all index
patients showed histiocyte infiltration (fig 1A). Filipin
staining of skin fibroblasts and cholesterol esterification
assays were performed in the National Referral Laboratory,
Adelaide, Australia (Dr M J Fietz). All patients had accumu-
lation of intracellular cholesterol similar to that shown in
fig 1B. The rate of cholesterol esterification was also
significantly reduced in these patients (table 1, normal range
.3 pmol/hour/mg protein).
METHODS
DNA was extracted from leucocytes using a standard method.
All the coding exons (26 amplicons) and the flanking regions
of the NPC1 gene were amplified by polymerase chain
reaction (PCR). The primer sequences are available on
request. Heteroduplexes were screened by denaturing high
performance liquid chromatography (DHPLC) using a
Transgenomic Wave Nucleic Acid Fragment Analysis
System (Transgenomic Inc, San Jose, CA). The protocol for
this has been described elsewhere.20 Equal amounts of PCR
product from the patient and a normal control were mixed
and then denatured and renatured by cooling from 95 C˚ to
25 C˚ over 70 minutes. Exons showing the presence of a
heteroduplex were sequenced using the BigDye Terminator
sequencing chemistry (ABI) and the ABI3100 automatic DNA
sequencer (Applied Biosystems, Foster City, CA).
Both filipin staining and cholesterol esterification assays
were performed using modified versions of the methods of
Vanier et al.15
RESULTS
All 26 exons of the NPC1 gene were amplified from each of
the five index patients and subjected to DHPLC. This revealed
the presence of heteroduplexes in all five patients.
Sequencing demonstrated a total of six different mutations,
2213C.A (S738Stop), 2903A.G (N968S), 3044G.T
(G1015V), 3100G.A (G1034R), 3761G.T (V1212L), and
1905del T/insATG (I635fs) (see table 1). The missense
mutations were located in exons 19 (N968S), 21 (G1015V,
















12/F * 8 years Psychomotor retardation, downward gaze palsy,
dysarthria, progressive intellectual decline, dysphagia,
pyramidal tract signs
High SI bilaterally in centrum
semiovale (T2-weighted image)
Positive 0.83 Yes
(Het) 7/M 4 years Downward gaze limitation, psychomotor retardation
in writing and finger tapping, frequent chocking
ND Positive 0.73 ND
2 G1034R
(Het)
9/F * 3 months Developmental delay, failure to thrive, ataxia,
psychomotor retardation, right preaxial polydactyly,
grand mal seizure, myoclonus, quadriparesis





5/M * 3 years Developmental delay, psychomotor retardation,
slow in speech
Unremarkable Positive 0.2 Yes
4 V1212L
(Het)
13/M * 5 years Vertical gaze limitation, ataxia, mental deterioration Cerebral and cerebellar atrophy,
dysgenesis of corpus callosum
Positive 2.1 Yes




20/M * 11 years Psychomotor retardation, ataxia, spasticity, dysphagia,
dysarthria, cognitive decline, urine and stool incontinence,
bilateral optic atrophy, partial seizure, myoclonus,
dystonia, akathisia
Cerebral atrophy, high SI in
the thoracic cord (T2-weighted
image)
Positive 1.4 Yes
Dec’d/M 13 years Psychomotor retardation, dysarthria, dysphagia,
cognitive decline, spasticity
ND ND ND ND
*Index patient.
CE, cholesterol esterification specific activity; dec’d, deceased; F, female; Het, compound heterozygous mutation; Hom, homozygous mutation; M, male; ND, not done; SI, signal intensity.
Figure 1 Pathological and neuroimaging manifestations in patients with NPC. (A) Light micrograph of a bone marrow aspirate showing the presence
of a foamy histiocyte. (B) Presence of perinuclear non-esterified cholesterol deposits in cultured fibroblasts visualised by fluorescence microscopy after
filipin staining. (C) Axial T2-weighted magnetic resonance image showing non-specific hyperintense areas in the white matter.
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G1034R), and 24 (V1212L). The nonsense mutation
(S738Stop) resulted in a premature stop codon at position
738. Likewise, the frameshift mutation (I635fs) encoded a
truncated protein with a premature stop codon at position
638. One of the missense mutations (V1212L) occurred in
two index patients (patients 1 and 4). Patient 3 was
homozygous for S738Stop while the other four mutations
each accounted for a single allele in the cohort. Only one
mutant allele each was identified in patients 2 and 4, G1034R
and V1212L, respectively. The six mutations were absent in
100 Taiwanese controls. In addition to the mutations, six
polymorphisms (H215R, I642M, I858V, N931N, R1266Q, and
R1314R) were also identified.
DISCUSSION
As is seen in many lipid storage disorders, the clinical
features of NPC are highly variable. There is considerable
variation in the age at which symptoms first appear as well as
in the progression and neurological manifestations of the
disease. Generally, the later the neurological symptoms
appear, the slower the progression of the disease. In our
patients, the younger the age of onset, the more severe was
the phenotype.
To date, more than 130 disease causing mutations have
been reported for NPC and most of these are missense
mutations (71%).15 Only a small number of frequently
occurring mutations have been described, namely, I1061T
and P1007A (in individuals of western European descent),
R518Q (Japanese), and P474L (Italian). None of these was
detected in the present study. More than a third of the NPC1
mutations are concentrated within the cysteine-rich luminal
loop of NPC1. The cysteine-rich loop contains a ring-finger
motif and is a likely site for functionally significant protein–
protein interactions.22 23 Three of the missense mutations
detected in this study are located within the cysteine-rich
loop (N968S, G1015V, and G1034R). However, none occurs in
the hot spot region (residues 927–958). The fourth missense
mutation, V1212L, occurs in transmembrane domain XII (TM
XII), which is located in the mutation-rich region homo-
logous to PTC1. Mutations I635fs and S738Stop introduce
premature stop codons at amino acids 638 (TM IV) and 738
(TM VI), respectively. None of the six novel mutations was
detected in 100 Taiwanese controls indicating that it is likely
that these six mutant alleles are pathogenic.
For two of the five patients examined in this study only
one mutation to the NPC1 gene was detected. Given the
clinical and biochemical presentations of these patients, it is
highly unlikely that both are true carriers of NPC. Therefore,
it remains possible that a second point mutation in these
patients was beyond the resolution of DHPLC and sequencing
analysis. Alternatively, these mutations could have resulted
from a large deletion or other genomic changes affecting
either the amplification of the relevant exons or the overall
structure of the gene. Amplification of the NPC1 cDNA or
genomic Southern analysis could be used to examine these
options further.
NPC is a complex neurological disorder with a broad range
of clinical presentations, routinely diagnosed using biochem-
ical analysis. Mutation screening provides an alternative
means of confirming the diagnosis of NPC. In addition, the
detection of both causative mutations allows carrier screen-
ing of family members as well as enabling rapid and accu-
rate prenatal testing by mutation analysis of DNA from fetal
cells.
In summary, we have described the mutation screening of
five Taiwanese/Chinese patients with NPC, resulting in the
detection of six novel NPC1 mutations. This is the first report
of NPC1 mutations in patients from this ethnic background.
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68 year old hypertensive woman was referred to the
neurology department having experienced a sudden
weakness in mastication and mild dysarthria. When
the patient was asked to protrude her tongue, a left lingual
paresis became evident (fig 1); however, the tongue was
normal while at rest in the mouth. Neurological examination
was otherwise normal.
A brain computed tomogram gave evidence of a small
haematoma limited to the posterior limb of the right internal
capsule (fig 2). No other abnormal radiological findings were
shown to be present on successive brain magnetic resonance
imaging.
Facial and lingual hemiparesis with mild limb involvement
have been previously described in capsular genu syndrome,
suggesting that motor corticopontine and corticocobulbar
fibres are situated more in the genu of the internal capsule.
Each hypoglossal nucleus receives impulses from both sides
of the cortex but the genioglossus muscle probably has
crossed unilateral innervation, thus an isolated right sided
lesion of the upper motor neurone, in the internal capsule, is
capable of causing lingual paresis that is evident only when
the tongue is protruded. Differential diagnosis of sudden
lingual hemiparesis, if unilateral, include lesions of the 12th
nerve; atrophy and fasciculations of the tongue will also be
present subsequently. This nerve can be damaged in the
medulla (by conditions such as ischaemia or neoplasm) or
after it leaves the brainstem and the skull through the
hypoglossal foramen. Acute involvement of the hypoglossal
nerve may arise with carotid dissection in the neck.
Sudden bilateral sopranuclear lingual paresis has been
described with a bilateral cerebral infarction involving the
anterior opercular region, and manifests itself in facial and
pharyngeal diplegia.
The condition of this patient was unique because the
lingual paresis manifested itself without having any associa-
tion with other neurological findings and the lesion had
occurred in the posterior limb of the internal capsule.
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Figure 2 Haematoma visible in right internal capsule, CT scan.
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